This trial is testing whether adding bevacizumab to osimertinib will help patients with EGFR-mutated, stage IIIB-IV non-small cell lung cancer live longer, as compared to osimertinib alone.
- Stage IVA Lung Cancer
- Stage IIIB Lung Cancer
- Non-Squamous Non-Small Cell Lung Carcinoma
- Non-Small Cell Lung Carcinoma
- Stage IV Lung Cancer
- Stage IVB Lung Cancer
- Non-Small Cell Lung Cancer (NSCLC)
1 Primary · 5 Secondary · Reporting Duration: From randomization to documented disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or death from any cause, whichever occurs first, assessed up to 10 years
Side Effects for
2 Treatment Groups
Arm A (osimertinib)
1 of 2
Arm B (osimertinib, bevacizumab)
1 of 2
300 Total Participants · 2 Treatment Groups
Primary Treatment: Osimertinib · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 22 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What are some similar trials that have used Osimertinib in the past?
"Originally, osimertinib was studied in 2004 at Memoral Sloan Kettering Basking Ridge (Follow Up Only). So far, 1034 studies have been completed. There are currently 478 active clinical trials, many of which are based in Bethesda, Maryland." - Anonymous Online Contributor
How many candidates will be chosen for this experiment?
"That is correct, the clinicaltrials.gov website does show that this trial is currently enrolling patients. The trial was originally posted on October 22nd, 2020 and was most recently updated on October 27th, 2020. They are hoping to enroll 300 patients from 100 different locations." - Anonymous Online Contributor
What side effects does Osimertinib have on patients?
"Osimertinib has received a score of 3 for safety. This is due to Phase 3 trial data, which provides some evidence of efficacy as well as multiple rounds of data supporting safety." - Anonymous Online Contributor
What are the most common applications for Osimertinib?
"Osimertinib can be used to treat aggressive and recurrent cancers such as malignant neoplasms, platinum sensitive primary peritoneal cancer, and stage iv epithelial ovarian cancer." - Anonymous Online Contributor
Are people with the condition still able to participate in this research?
"That is correct. The clinical trial is currently recruiting patients. The first posting was on October 22, 2020, with the latest update on October 27, 2020. They are looking for 300 patients total from 100 different sites." - Anonymous Online Contributor